31,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
The study will provide evidence for evaluating and understanding the role of electroacupuncture in the treatment of Alzheimer's disease. 5 key findings →
Participants: 75 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
SCarlet RoAD (NCT01224106; WN25203), a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-year study of gantenerumab in prodromal AD, was the first global registration-enabling study using biomarker screening for entry and a single clinical endpoint for outcome. 3 key findings →
Design: clinical trial Participants: 312 Evidence: high
Full summary, score breakdown and related studies → Original source
This survey analyzes two national pharmacovigilance databases in order to determine the major adverse reactions observed with the use of cholinesterase inhibitors in dementia. 2 key findings →
Participants: 9,877 Evidence: low
Full summary, score breakdown and related studies → Original source
Treatment outcomes in CitAD showed modest, although statistically significant, influence of genetic variation at HTR2A and HTR2C loci. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The objective of this study was to compare the effect of multisensory stimulation environment (MSSE) and one-to-one activity sessions in the symptomatology of elderly individuals with severe dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
RVT-101 is a 5-hydroxytryptamine 6 (5-HT6) receptor antagonist for the treatment of dementia with a number of favorable properties including once daily dosing, lack of food effect, and low potential for drug interactions. 4 key findings →
Design: clinical trial Participants: 684 Evidence: high
Full summary, score breakdown and related studies → Original source
In total, 100 subjects completed the study. 5 key findings →
Design: clinical trial Participants: 100 Evidence: high
Full summary, score breakdown and related studies → Original source
Two‐hundred and sixteen only subjects were randomized across 28 French expert clinical sites. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
ARIA-H represents a spectrum of MRI findings due to haemosiderin deposition that appears to be related to impaired vascular integrity. 3 key findings →
Design: open-label trial Participants: 262 Evidence: low
Full summary, score breakdown and related studies → Original source
These data confirm the challenges of correctly diagnosing AD without using biomarkers. 2 key findings →
Participants: 2,052 Evidence: low
Full summary, score breakdown and related studies → Original source
This review highlights a great heterogeneity in RCTs design of drugs for A/A in AD and some key methodological issues such as definition of A/A, choice of outcome measures and caregiver participation that could be addressed by an expert consensus to optimize future trials design. 5 key findings →
Participants: 18 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The predefined superiority of donepezil to the placebo was not confirmed in either active group in the primary analysis. 5 key findings →
Participants: 142 Evidence: low
Full summary, score breakdown and related studies → Original source
These same brain areas were then assessed in a cohort of patients with Alzheimer’s disease versus a healthy older reference group, using a region of interest approach combined with standard structural (MRI), metabolic (fluorodeoxyglucose-PET) and amyloid ligand (florbetapir-PET) neuroimaging. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
The purpose of the study was to evaluate the influences of cholinesterase inhibitors on sleep pattern and sleep disturbance. 3 key findings →
Participants: 87 Evidence: low
Full summary, score breakdown and related studies → Original source
The addition of memantine resulted in stabilization of the Mini-Mental State Examination scores and Hasegawa dementia rating for 6 months, and then significantly declined at 12 months in both subgroups. 5 key findings →
Participants: 61 Evidence: low
Full summary, score breakdown and related studies → Original source
Treatments were generally well tolerated and adverse events (AEs) were seen at similar rates across all treatment groups, with the exception that more injection site reactions were seen in the groups with a higher level of adjuvant. 3 key findings →
Participants: 332 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Aducanumab (BIIB037) is a human monoclonal antibody selective for aggregated forms of beta-amyloid peptide being investigated as a disease-modifying treatment for AD. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
Pioglitazone is currently undergoing clinical trials for treatment of Alzheimer's disease (AD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Furthermore, numerous reports indicate that amyloid-β interacts with butyrylcholinesterase and apolipoprotein-E. In the case of butyrylcholinesterase, the results indicated that amyloid-β interacts with a putative activation site at the mouth of its catalytic tunnel, most likely leading to increased acetylcholine influx into the catalytic site, and thereby increasing the intrinsic catalytic rate of butyrylcholinesterase. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Many insults, including trauma, ischemia, infection, inflammation, and neurodegeneration, result in irreversible damage to the central nervous system. 3 key findings →
Design: clinical trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Cerebral amyloid angiopathy-related inflammation (CAA-ri), a rare form of vasculitis associated with amyloid-β (Aβ) deposition in vessel walls, has been proposed as a spontaneous human model of the amyloid-related imaging abnormalities (ARIA) occurring after anti-Aβ immunotherapy for the treatment of Alzheimer's disease (AD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Amyloid-related imaging abnormalities (ARIA), thought to reflect immune responses to vascular amyloid, have been detected in several amyloid-modifying therapy trials for Alzheimer's disease (AD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Florbetaben is a fluorine-18 ( 18 F)-labeled stilbene derivative that was developed as a positron emission tomography (PET) tracer for routine clinical application to visualize β-amyloid plaques in the Alzheimer's disease (AD) brain. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Amyloid-related imaging abnormalities (ARIA) represent the major severe side effect of amyloid-beta (Aβ) immunotherapy for Alzheimer's disease (AD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is a complex and progressive neurodegenerative disorder. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 31,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,780 records, built mostly from automated pulls of Europe PMC (66% of the library) and OpenAlex (16%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,052 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events